- In April 2023, Alkermes plc, a leading pharmaceutical company focused on neuroscience, announced positive results from a real-world study of its long-acting injectable medication for alcohol dependence, demonstrating improved adherence and reduced relapse rates in a broader patient population. This data supports the long-term effectiveness of their therapy
- In March 2023, Indivior PLC, a global pharmaceutical company, initiated a new Phase 3 clinical trial for an investigational opioid-free medication designed to reduce heavy drinking in individuals with alcohol use disorder, signaling potential for a novel non-opioid treatment option. This advancement aims to provide an alternative for patients seeking non-addictive treatments
- In March 2023, Merck & Co., Inc., a global healthcare leader, announced a strategic collaboration with a digital health company to develop an integrated digital platform that combines pharmacotherapy with virtual behavioral support for alcohol dependency. This partnership aims to enhance patient engagement and treatment outcomes
- In February 2023, Pfizer Inc., a major pharmaceutical company, introduced a new patient assistance program aimed at increasing access to its medications for alcohol dependence for underserved populations, demonstrating a commitment to addressing health disparities. This initiative seeks to improve affordability and accessibility
- In January 2023, Sanofi, a global pharmaceutical company, presented preclinical data for a novel compound targeting specific brain pathways involved in alcohol cravings, showing promising results in animal models and suggesting a potential new class of medication for AUD. This development could lead to more targeted and effective treatments
